Affiliation:
1. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University
Abstract
In the fall of 2019, global health was confronted with a new RNA virus — severe acute respiratory syndrome coronavirus 2 SARS-CoV-2. Against the background of the rapid spread of infection, research centers around the world began to develop specific vaccines against COVID-19, using the accumulated experience and empirical data on the stereotypes of the structure and physiology of other viral agents of this family (severe acute respiratory syndrome virus (SARS) and Middle East respiratory syndrome (MERS). However, even before the development of anti-COVID vaccines, it was suggested that they are probably less effective in a number of individuals, in particular, in people who are overweight or obese. This hypothesis arose on the basis of past studies using vaccines for other purposes in this categories of people, as well as in numerous experiments on mice, thanks to which scientists came to the conclusion that, due to an excess amount of adipose tissue in the body, there is a state of a permanent inflammatory process, some immune dysfunction, and, as a result, a reduced local and systemic response. resistance against bacterial and viral agents.In this literature review, using current publications obtained by searching for “covid-19 vaccination and obesity” and “vaccination and obesity” in the PubMed databases and “covid-19 vaccination and obesity” and “vaccination and obesity” in the e- Library discusses changes in the immune response both to infection itself and to immunization in the presence of overweight or obesity.
Publisher
Endocrinology Research Centre
Subject
Public Health, Environmental and Occupational Health,Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference30 articles.
1. WHO [Internet] 2021. Fact sheet on overweight and obesity: World Health Organization. [cited 16.02.2023] Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Rychter AM, Zawada A, Ratajczak AE, e Should patients with obesity be more afraid of COVID‐19? Obes Rev. 2020;21(9):e13083. doi: https://doi.org/10.1111/obr.13083
3. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med. 2010;235(12):1412-1424. doi: https://doi.org/10.1258/ebm.2010.010227
4. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-574. doi: https://doi.org/10.1016/S0140-6736(20)30251-8
5. Rokkam VRP, Vegunta R, Prudhvi K, et al. “Weighing” the risks and benefits – Thromboprophylaxis challenges in obese COVID-19 patients. Obes Med. 2020;(19):100284. doi: https://doi.org/10.1016/j.obmed.2020.100284